Sadra Medical Journal

Comparison of Depression, Anxiety, Stress, and Health-Related Quality of Life in Patients with Recurrent and Acute Vulvovaginal Candidiasis

Document Type : Original Article

Authors

Fahimeh Baghbani 1
Laleh Tajadiny 2
Setareh Agha Kuchak Afshari 3
Maryam Soleimani Houni 4
Ali Khaksar Baniasadi 3
Masumeh Ghazanfarpour 1
Firoozeh Mirzaee 1
Maryam Dehghanipour 5
Atefeh Ahmadi 6

1 Reproductive and Family Health Research Center, Kerman University of Medical Sciences, Kerman, Iran

2 Student Research Committee, Razi Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran

3 Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran

4 School of Nursing and Midwifery, Jiroft University of Medical Sciences, Jiroft, Iran

5 Deputy of Health, Sirjan University of Medical Sciences, Sirjan, Iran

6 Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran

https://doi.org/10.30476/smsj.2026.107104.1646
Abstract
Introduction: Vulvovaginal candidiasis is one of the most common fungal infections in women, affecting approximately 80% of them. The recurrent form, due to prolonged antifungal use and drug resistance, reduces quality of life and increases treatment costs. This study aimed to compare depression, anxiety, stress, and quality of life in women with recurrent and non-recurrent (acute) vulvovaginal candidiasis.
Methods: Demographic data of women aged 18–45 years with recurrent and non-recurrent vulvovaginal candidiasis were collected at healthcare centers in Kerman and Sirjan in 2021 using a researcher-designed questionnaire. Patient classification (recurrent vs. non-recurrent) was based on the number of infection episodes per year. Stress, anxiety, and depression were assessed using a questionnaire derived from the Depression, Anxiety, and Stress Scale (DASS), and quality of life was evaluated using the 36-Item Short Form Health Survey (SF-36) questionnaire (8 items and 6 components). A total of 84 women (42 in each group) were enrolled in the study. Data were analyzed using SPSS software, version 16.
Results: Questionnaire analysis revealed that quality of life in women with acute vulvovaginal candidiasis was significantly higher than in those with recurrent vulvovaginal candidiasis (P=0.03). Furthermore, the quality-of-life domains of physical functioning (P=0.021), physical role (P=0.029), emotional role (P=0.037), and health changes (P=0.002) showed significant differences. However, no significant differences were found between the two groups regarding depression (P=0.674), anxiety (P=0.938), or stress (P=0.615).
Conclusion: Vulvovaginal candidiasis substantially affected women’s quality of life and mental health, although the severity varied by disease type. Therefore, it is necessary to focus clinical interventions on mitigating these effects and to conduct further studies with control groups.

Keywords

Candidiasis
Vulvovaginal؛ Quality of Life؛ Depressive Disorder؛ Depression؛ Anxiety؛ Stress
Psychological
  1. Moshfeghy Z, Tahari S, Janghorban R, Najib FS, Mani A, Sayadi M. Association of sexual function and psychological symptoms including depression, anxiety and stress in women with recurrent vulvovaginal candidiasis. J Turk Ger Gynecol Assoc. 2020;21(2):90-6.
  2. Brown H, Drexler M. Improving the diagnosis of vulvovaginitis: perspectives to align practice, guidelines, and awareness. Popul Health Manag. 2020;23(Suppl 1):S3-12.
  3. Wu M, Kherlopian A, Wijaya M, Fischer G. Quality of life impact and treatment response in vulval disease: comparison of 3 common conditions using the Vulval Quality of Life Index. Australas J Dermatol. 2022;63(4):e320-8.
  4. Nguyen Y, Lee A, Fischer G. Quality of life in patients with chronic vulvovaginal candidiasis: a before and after study on the impact of oral fluconazole therapy. Australas J Dermatol. 2017;58(4):e176-81.
  5. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15-21.
  6. Emeribe AU, Nasir IA, Onyia J, Ifunanya AL. Prevalence of vulvovaginal candidiasis among nonpregnant women attending a tertiary health care facility in Abuja, Nigeria. Res Rep Trop Med. 2015;6:37-42.
  7. Kiasat N, Rezaei-Matehkolaei A, Mahmoudabadi AZ, Mohamadpour KH, Molavi S, Khoshayand N. Prevalence of vulvovaginal candidiasis in Ahvaz, southwest Iran: a semi-large scale study. Jundishapur J Microbiol. 2019;12(3):1-6.
  8. Khaksar Baniasadi A, Ayatollahi Mosavi SA, Sharifi I, Bamorovat M, Salari S, Ahmadi A, et al. Vulvovaginal candidiasis in Iranian women: molecular identification and antifungal susceptibility pattern. J Obstet Gynaecol Res. 2022;48(12):3292-303.
  9. Jannati B, Pourdad A, Izadjoo A, Zarrinfar H, Najafzadeh MJ, Fata A. The prevalence of non-albicans Candida and Candida mixed-species in vulvovaginal candidiasis in Northeast Iran. Clin Exp Obstet Gynecol. 2024;51(3):77.
  10. Azhrak P, Kamalifard M, Mirghafourvand M, Khedri S, Hasanpour S. The association between vaginal candidiasis and health-promoting lifestyle in Iranian women: a cross-sectional study. J Educ Health Promot. 2020;8(4):412-7.
  11. Rostami O, Zarrinfar H. Distribution of Candida albicans and non-albicans Candida species causing vaginitis in Iran: a review. J Patient Saf Qual Improv. 2025;13(1):1-10.
  12. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340-5.
  13. Weissenbacher T, Witkin SS, Ledger WJ, Tolbert V, Gingelmaier A, Scholz C, et al. Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet. 2009;279(2):125-9.
  14. Zhu YX, Li T, Fan SR, Liu XP, Liang YH, Liu P. Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. Health Qual Life Outcomes. 2016;14:65.
  15. Da Luz RA, de Deus JM, Valadares AL, Conde DM. Evaluation of sexual function in Brazilian women with and without chronic pelvic pain. J Pain Res. 2018;11:2761-7.
  16. Lietz A, Eckel F, Kiss H, Noe-Letschnig M, Farr A. Quality of life in women with chronic recurrent vulvovaginal candidosis: a sub-analysis of the prospective multicentre phase IIb/III Prof-001 study. Mycoses. 2023;66(9):767-73.
  17. Foster DC, Falsetta ML, Woeller CF, Pollock SJ, Song K, Bonham A, et al. Site-specific mesenchymal control of inflammatory pain to yeast challenge in vulvodynia-afflicted and pain-free women. Pain. 2015;156(3):386-96.
  18. Falsetta ML, Foster DC, Woeller CF, Pollock SJ, Bonham AD, Haidaris CG, et al. Identification of novel mechanisms involved in generating localized vulvodynia pain. Am J Obstet Gynecol. 2015;213(1):38.e1-12.
  19. Yano J, Sobel JD, Nyirjesy P, Sobel R, Williams VL, Yu Q, et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019;19(1):48.
  20. Dovnik A, Golle A, Novak D, Arko D, Takac I. Treatment of vulvovaginal candidiasis: a review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(1):5-7.
  21. Rosati D, Bruno M, Jaeger M, Ten Oever J, Netea MG. Recurrent vulvovaginal candidiasis: an immunological perspective. Microorganisms. 2020;8(2):144.
  22. Fukazawa EI, Witkin SS, Robial R, Vinagre JG, Baracat EC, Linhares IM. Influence of recurrent vulvovaginal candidiasis on quality of life issues. Arch Gynecol Obstet. 2019;300(3):647-50.
  23. Sasani E, Rafat Z, Ashrafi K, Salimi Y, Zandi M, Soltani S, et al. Vulvovaginal candidiasis in Iran: a systematic review and meta-analysis on the epidemiology, clinical manifestations, demographic characteristics, risk factors, etiologic agents and laboratory diagnosis. Microb Pathog. 2021;154:104802.
  24. Arastehfar A, Kargar ML, Mohammadi SR, Roudbary M, Ghods N, Haghighi L, et al. A high rate of recurrent vulvovaginal candidiasis and therapeutic failure of azole derivatives among Iranian women. Front Microbiol. 2021;12:655069.
  25. Irving G, Miller D, Robinson A, Reynolds S, Copas AJ. Psychological factors associated with recurrent vaginal candidiasis: a preliminary study. Sex Transm Infect. 1998;74(5):334-8.
  26. RAND Corporation. 36-item short form survey (SF-36) scoring instructions. Santa Monica: RAND Corporation; 2023.
  27. Lovibond SH. Manual for the depression anxiety stress scales. Sydney: Psychology Foundation; 1995.
  28. Fukazawa EI, Witkin SS, Robial R, Vinagre JG, Baracat EC, Linhares IM. Influence of recurrent vulvovaginal candidiasis on quality of life issues. Arch Gynecol Obstet. 2019;300(3):647-50.
  29. Aballea S, Guelfucci F, Wagner J, Khemiri A, Dietz JP, Sobel J, et al. Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169.
  30. Rashad MR, Mohamed HSE, Emara HA, Elsabiey FI, Salim HM. Quality of life among women diagnosed with vaginal infection. Zagazig Nurs J. 2022;18(1):52-69.
  31. Reichman O, Margesson LJ, Rasmussen CA, Lev-Sagie A, Sobel JD. Algorithms for managing vulvovaginal symptoms—a practical primer. Curr Infect Dis Rep. 2019;21(10):40.
  32. Lietz A, Eckel F, Kiss H, Noe-Letschnig M, Farr A. Quality of life in women with chronic recurrent vulvovaginal candidosis: a sub-analysis of the prospective multicentre phase IIb/III Prof-001 study. Mycoses. 2023;66(9):767-73.
Sadra Medical Journal
Volume 14, Issue 2
Spring 2026
Pages 301-312

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us